United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - cephalexin (unii: obn7uds42y) (cephalexin - unii:obn7uds42y) -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - cephalexin monohydrate - unknown - cephalexin monohydrate antibiotic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - cephalexin monohydrate - unknown - cephalexin monohydrate antibiotic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - cephalexin monohydrate - unknown - cephalexin monohydrate antibiotic active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes. cephalexin is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis. cephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis. cephalexin is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the development of drug-resistant bacteria and maintain the effectiveness of cep

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg in 5 ml - cephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes. cephalexin is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis. cephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis. cephalexin is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the development of drug-resistant bacteria and maintain the effectiveness of cep

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules usp are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by and . (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) streptococcus pneumoniae streptococcus pyogenes otitis media due to , , , , and . streptococcus pneumoniae haemophilus influenzae staphylococcus aureus streptococcus pyogenes moraxella catarrhalis skin and skin structure infections caused by and/or . staphylococcus aureus streptococcus pyogenes bone infections caused by and/or .

United States - English - NLM (National Library of Medicine)

unit dose services - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 500 mg - cephalexin capsules usp are indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes . cephalexin capsules usp are indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis . cephalexin capsules usp are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin capsules usp are indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis . cephalexin capsules usp are indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the dev

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 500 mg - cephalexin capsules usp are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes. (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus, streptococcus pyogenes, and moraxella catarrhalis. skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes. bone infections caused by staphylococcus aureus and/or proteus mirabilis. genitourinary tract infections, including acute prostatitis, caused by escherich

United States - English - NLM (National Library of Medicine)

unit dose services - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules, usp are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms:   respiratory tract infections caused by and (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.   cephalexin capsules, usp are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin capsules, usp in the subsequent prevention of rheumatic fever are not available at present.)   otitis media due to , , , and   skin and skin structure infections caused by and/or   bone infections caused by and/or   genitourinary tract infections, including acute prostatitis, caused by , , and   — culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.   to reduce the development of drug-resistant bacteria and maint